A 53‐year‐old female with suprasellar mass

temozolomide are the primary treatment options when complete surgical resection is risky. Some studies on targeted drugs and cellular immunotherapy, such as Imipridone ONC201 and the IDO1 inhibitor Indoxi-mod are in the early phases of clinical activity. In addition, the use of immunotherapy is being trialed as an option. Chimeric antigen receptor T-cell therapy and immune-modulating antibodies are also under research. Our patient, despite surgical resection followed by con-current chemoradiotherapy, experienced rapid regrowth of the tumor, which lead to her demise 6 months after surgery.